{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:47:53Z","timestamp":1795024073416,"version":"4.10.2"},"reference-count":81,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Syringocystadenocarcinoma papilliferum (SCACP) is a rare adnexal carcinoma and the malignant counterpart of syringocystadenoma papilliferum (SCAP), which is commonly located on the head and neck and may arise in association with a nevus sebaceus. RAS mutations have been identified in both SCAP and nevus sebaceus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To evaluate the clinicopathologic and molecular features of SCACPs, which have not been previously explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>We obtained 11 SCACPs from 6 institutions and reviewed the clinicopathologic features. We also performed molecular profiling using next-generation sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>The cohort comprised 6 women and 5 men with ages ranging from 29 to 96 years (mean, 73.6 years). The neoplasms occurred on the head and neck (n = 8; 73%) and extremities (n = 3; 27%). Three tumors possibly arose in a nevus sebaceus. A total of 4 cases showed at least carcinoma in situ (adenocarcinoma, n = 3; squamous cell carcinoma [SCC], n = 1), and 7 cases were invasive (SCC, n = 5; mixed adenocarcinoma + SCC, n = 2). A total of 8 of 11 cases (73%) had hot spot mutations consisting of HRAS (n = 4), KRAS (n = 1), BRAF (n = 1), TP53 (n = 4), ATM (n = 2), FLT3 (n = 1), CDKN2A (n = 1), and PTEN (n = 1). All 4 cases with HRAS mutations occurred on the head and neck, whereas the KRAS mutation occurred on the extremity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>RAS-activating mutations were detected in 50% of the cases, of which most (80%) involved HRAS and occurred on the head and neck, which shows overlapping features with SCAP, supporting that a subset may arise as a result of malignant transformation and likely an early oncogenic event.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2022-0474-oa","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T12:03:27Z","timestamp":1681905807000},"page":"215-222","source":"Crossref","is-referenced-by-count":14,"title":["Molecular Profiling of Syringocystadenocarcinoma Papilliferum Reveals\n                    <i>RAS<\/i>\n                    -Activating Mutations"],"prefix":"10.5858","volume":"148","author":[{"given":"Kristine M.","family":"Cornejo","sequence":"first","affiliation":[{"name":"From the Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts (Cornejo, Nazarian)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts (Hutchinson, O\u2019Donnell, Meng, Tomaszewicz)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts (Hutchinson, O\u2019Donnell, Meng, Tomaszewicz)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuling","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts (Hutchinson, O\u2019Donnell, Meng, Tomaszewicz)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Tomaszewicz","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts (Hutchinson, O\u2019Donnell, Meng, Tomaszewicz)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara C.","family":"Shalin","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas (Shalin)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Cassarino","sequence":"additional","affiliation":[{"name":"Southern California Permanente Medical Group, Sunset Medical Center, Department of Pathology, Los Angeles, California (Cassarino)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May P.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Health System, Ann Arbor, Michigan (Chan)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Quinn","sequence":"additional","affiliation":[{"name":"Massachusetts General Physicians Organization Dermatopathology Associates, Newton, Massachusetts (Quinn)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Googe","sequence":"additional","affiliation":[{"name":"the Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (Googe)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalynn M.","family":"Nazarian","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts (Cornejo, Nazarian)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"issue":"(6)","key":"2024013013503174700_i1543-2165-148-2-215-b01","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/cup.12934","article-title":"Syringocystadenocarcinoma papilliferum: clinicopathologic analysis of 10 cases","volume":"44","author":"Zhang","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"(4)","key":"2024013013503174700_i1543-2165-148-2-215-b02","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2559.1980.tb02939.x","article-title":"Sweat-gland carcinomas: prognosis related to histological type","volume":"4","author":"Dissanayake","year":"1980","journal-title":"Histopathology"},{"issue":"(5)","key":"2024013013503174700_i1543-2165-148-2-215-b03","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1046\/j.1365-2133.2002.05027.x","article-title":"An immunohistochemical and ultrastructural study of syringocystadenoma papilliferum","volume":"147","author":"Yamamoto","year":"2002","journal-title":"Br J Dermatol"},{"issue":"(8)","key":"2024013013503174700_i1543-2165-148-2-215-b04","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.5858\/2009-0399-CR.1","article-title":"Diagnostic pitfalls in syringocystadenocarcinoma papilliferum: case report and review of the literature","volume":"134","author":"Leeborg","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"(5)","key":"2024013013503174700_i1543-2165-148-2-215-b05","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1067\/mjd.2001.117723","article-title":"Syringocystadenocarcinoma papilliferum: case report and immunohistochemical comparison with its benign counterpart","volume":"45","author":"Ishida-Yamamoto","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"(2)","key":"2024013013503174700_i1543-2165-148-2-215-b06","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0560.2009.01419.x","article-title":"Syringocystadenocarcinoma papilliferum in a linear nevus verrucosus","volume":"38","author":"Hoekzema","year":"2011","journal-title":"J Cutan Pathol"},{"issue":"(4)","key":"2024013013503174700_i1543-2165-148-2-215-b07","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/DAD.0000000000001285","article-title":"Syringocystadenoma papilliferum of the anogenital area and buttocks: a report of 16 cases, including human papillomavirus analysis and HRAS and BRAF V600 mutation studies","volume":"41","author":"Konstantinova","year":"2019","journal-title":"Am J Dermatopathol"},{"issue":"(2)","key":"2024013013503174700_i1543-2165-148-2-215-b08","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.humpath.2014.11.002","article-title":"Activating mutations in the RAS\/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum","volume":"46","author":"Shen","year":"2015","journal-title":"Hum Pathol"},{"issue":"(7)","key":"2024013013503174700_i1543-2165-148-2-215-b09","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.2316","article-title":"Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome","volume":"44","author":"Groesser","year":"2012","journal-title":"Nat Genet"},{"issue":"(1)","key":"2024013013503174700_i1543-2165-148-2-215-b10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ajmg.a.37376","article-title":"Somatic BRAF c.1799T&gt;A p.V600E mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities","volume":"170A","author":"Watanabe","year":"2016","journal-title":"Am J Med Genet A"},{"issue":"(3)","key":"2024013013503174700_i1543-2165-148-2-215-b11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/cup.13093","article-title":"Contiguous verrucous proliferations in syringocystadenoma papilliferum: a retrospective analysis with additional evaluation via mutation-specific BRAFV600E immunohistochemistry","volume":"45","author":"Friedman","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"(3)","key":"2024013013503174700_i1543-2165-148-2-215-b12","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/jid.2012.379","article-title":"Whole-exome sequencing reveals somatic mutations in HRAS and KRAS, which cause nevus sebaceus","volume":"133","author":"Levinsohn","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"(3)","key":"2024013013503174700_i1543-2165-148-2-215-b13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/jid.2012.377","article-title":"Mosaic activating RAS mutations in nevus sebaceus and nevus sebaceus syndrome","volume":"133","author":"Sun","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"(10)","key":"2024013013503174700_i1543-2165-148-2-215-b14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/DAD.0000000000000687","article-title":"Syringocystadenocarcinoma papilliferum in situ, a variant of cutaneous adenocarcinoma in situ: a case report with literature review","volume":"38","author":"Chen","year":"2016","journal-title":"Am J Dermatopathol"},{"issue":"(4)","key":"2024013013503174700_i1543-2165-148-2-215-b15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ajpath.2017.12.003","article-title":"Next-generation sequencing to detect deletion of RB1 and ERBB4 genes in chromophobe renal cell carcinoma: a potential role in distinguishing chromophobe renal cell carcinoma from renal oncocytoma","volume":"188","author":"Liu","year":"2018","journal-title":"Am J Pathol"},{"issue":"(3)","key":"2024013013503174700_i1543-2165-148-2-215-b16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/his.12955","article-title":"Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease","volume":"69","author":"Kamionek","year":"2016","journal-title":"Histopathology"},{"issue":"(6)","key":"2024013013503174700_i1543-2165-148-2-215-b17","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.humpath.2014.02.001","article-title":"BRAF\/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis","volume":"45","author":"Cornejo","year":"2014","journal-title":"Hum Pathol"},{"issue":"(1)","key":"2024013013503174700_i1543-2165-148-2-215-b18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.celrep.2012.12.008","article-title":"Deciphering signatures of mutational processes operative in human cancer","volume":"3","author":"Alexandrov","year":"2013","journal-title":"Cell Rep"},{"issue":"(1)","key":"2024013013503174700_i1543-2165-148-2-215-b19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/php.12377","article-title":"UV signature mutations","volume":"91","author":"Brash","year":"2015","journal-title":"Photochem Photobiol"},{"issue":"(1)","key":"2024013013503174700_i1543-2165-148-2-215-b20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1073\/pnas.91.1.360","article-title":"UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement","volume":"91","author":"Nakazawa","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"(10)","key":"2024013013503174700_i1543-2165-148-2-215-b21","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1038\/jid.2015.180","article-title":"Somatic V600E BRAF mutation in linear and sporadic syringocystadenoma papilliferum","volume":"135","author":"Levinsohn","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2024013013503174700_i1543-2165-148-2-215-b22","first-page":"9056209","article-title":"Metastatic Syringocystadenocarcinoma papilliferum: a case report, tumor genomic profiling, and literature review","volume":"2020","author":"Altunel","year":"2020","journal-title":"Case Rep Oncol Med"},{"issue":"(1)","key":"2024013013503174700_i1543-2165-148-2-215-b23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/cup.13572","article-title":"Syringocystadenoma papilliferum associated with verrucous carcinoma of the skin in the same lesion: report of four cases","volume":"47","author":"Alegria-Landa","year":"2020","journal-title":"J Cutan Pathol"},{"key":"2024013013503174700_i1543-2165-148-2-215-b24","first-page":"8076649","article-title":"Syringocystadenocarcinoma papilliferum in a fifteen-year-old girl: a case report and review of the literature","volume":"2022","author":"Halsey","year":"2022","journal-title":"Case Rep Dermatol Med"},{"key":"2024013013503174700_i1543-2165-148-2-215-b25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.humpath.2015.12.015","article-title":"Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations","volume":"51","author":"Harms","year":"2016","journal-title":"Hum Pathol"},{"issue":"(3)","key":"2024013013503174700_i1543-2165-148-2-215-b26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pathol.2017.10.011","article-title":"Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas","volume":"50","author":"Bosic","year":"2018","journal-title":"Pathology"},{"issue":"(9)","key":"2024013013503174700_i1543-2165-148-2-215-b27","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1172\/JCI126185","article-title":"Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma","volume":"129","author":"Sekine","year":"2019","journal-title":"J Clin Invest"},{"issue":"(9)","key":"2024013013503174700_i1543-2165-148-2-215-b28","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/cup.14008","article-title":"Poroid adnexal skin tumors with YAP1 fusions exhibit similar histopathologic features: a series of six YAP1-rearranged adnexal skin tumors","volume":"48","author":"Prieto-Granada","year":"2021","journal-title":"J Cutan Pathol"},{"issue":"(5)","key":"2024013013503174700_i1543-2165-148-2-215-b29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.semdp.2015.02.010","article-title":"BRAF V600E mutation-specific antibody: a review","volume":"32","author":"Ritterhouse","year":"2015","journal-title":"Semin Diagn Pathol"},{"issue":"(11)","key":"2024013013503174700_i1543-2165-148-2-215-b30","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.humpath.2013.06.018","article-title":"Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas","volume":"44","author":"Routhier","year":"2013","journal-title":"Hum Pathol"},{"issue":"(11)","key":"2024013013503174700_i1543-2165-148-2-215-b31","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.humpath.2014.07.014","article-title":"Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays","volume":"45","author":"Fisher","year":"2014","journal-title":"Hum Pathol"},{"key":"2024013013503174700_i1543-2165-148-2-215-b32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jocn.2019.05.002","article-title":"Pilocytic astrocytoma vs. ganglioglioma: progression vs. misdiagnosis, and implications in BRAF testing","volume":"66","author":"Yoon","year":"2019","journal-title":"J Clin Neurosci"},{"issue":"(10)","key":"2024013013503174700_i1543-2165-148-2-215-b33","doi-asserted-by":"crossref","first-page":"e47290","DOI":"10.1371\/journal.pone.0047290","article-title":"Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses","volume":"7","author":"Le","year":"2012","journal-title":"PLoS One"},{"issue":"(7)","key":"2024013013503174700_i1543-2165-148-2-215-b34","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/modpathol.2011.48","article-title":"A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas","volume":"24","author":"Dias-Santagata","year":"2011","journal-title":"Mod Pathol"},{"key":"2024013013503174700_i1543-2165-148-2-215-b35","first-page":"638294","article-title":"Chemoradiotherapy in a case of malignant syringocystadenocarcinoma papilliferum of vulva with locoregional failure","volume":"2015","author":"Rao","year":"2015","journal-title":"Case Rep Oncol Med"},{"issue":"(9)","key":"2024013013503174700_i1543-2165-148-2-215-b36","first-page":"19620","article-title":"Syringocystadenocarcinoma papilliferum: a rare tumor with a favorable prognosis","volume":"19","author":"Peterson","year":"2013","journal-title":"Dermatol Online J"},{"issue":"(1)","key":"2024013013503174700_i1543-2165-148-2-215-b37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/DAD.0000000000000370","article-title":"A histological snapshot of hypothetical multistep progression from nevus sebaceus to invasive syringocystadenocarcinoma papilliferum","volume":"38","author":"Parekh","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"2024013013503174700_i1543-2165-148-2-215-b38","first-page":"685","article-title":"Syringocystadenoma papilliferum with malignant evolution: presentation of a case","volume":"1009","author":"Seco Navedo","year":"1982","journal-title":"Ann Dermatol Venereol"},{"issue":"(1)","key":"2024013013503174700_i1543-2165-148-2-215-b39","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1097\/SCS.0b013e31826cffc6","article-title":"Syringocystadenocarcinoma papilliferum with squamous cell carcinoma differentiation and with locoregional metastasis","volume":"24","author":"Arslan","year":"2013","journal-title":"J Craniofac Surg"},{"issue":"(4)","key":"2024013013503174700_i1543-2165-148-2-215-b40","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/DAD.0b013e318235dd34","article-title":"Syringocystadenocarcinoma papilliferum with transition to areas of squamous differentiation: a case report and review of the literature","volume":"34","author":"Zhang","year":"2012","journal-title":"Am J Dermatopathol"},{"issue":"(2)","key":"2024013013503174700_i1543-2165-148-2-215-b41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000381940","article-title":"Syringocystadenocarcinoma papilliferum in the perianal area","volume":"7","author":"Iga","year":"2015","journal-title":"Case Rep Dermatol"},{"issue":"(4)","key":"2024013013503174700_i1543-2165-148-2-215-b42","first-page":"22335","article-title":"Syringocystadenocarcinoma papilliferum with locoregional metastases","volume":"20","author":"Satter","year":"2014","journal-title":"Dermatol Online J"},{"issue":"(2)","key":"2024013013503174700_i1543-2165-148-2-215-b43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1524-4725.2009.01403.x","article-title":"Syringocystadenocarcinoma papilliferum","volume":"36","author":"Sroa","year":"2010","journal-title":"Dermatol Surg"},{"issue":"(5)","key":"2024013013503174700_i1543-2165-148-2-215-b44","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4103\/ijdvl.IJDVL_755_16","article-title":"Syringocystadenocarcinoma papilliferum with coexisting trichoblastoma: a case report with review of literature","volume":"83","author":"Muthusamy","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"(3)","key":"2024013013503174700_i1543-2165-148-2-215-b45","first-page":"195","article-title":"Syringocystadenocarcinoma papilliferum: a rare malignant sweat gland tumor","volume":"16","author":"Yao","year":"2018","journal-title":"Skinmed"},{"issue":"(7)","key":"2024013013503174700_i1543-2165-148-2-215-b46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamadermatol.2017.0397","article-title":"An unusual case of syringocystadenocarcinoma papilliferum in situ with macular amyloidosis","volume":"153","author":"Singh","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"(2)","key":"2024013013503174700_i1543-2165-148-2-215-b47","first-page":"168","article-title":"Well-differentiated squamous cell carcinoma arising in syringocystadenoma papilliferum","volume":"10","author":"Singh","year":"2019","journal-title":"Indian Dermatol Online J"},{"issue":"(6)","key":"2024013013503174700_i1543-2165-148-2-215-b48","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.jcjo.2017.05.001","article-title":"Squamous cell carcinoma arising from syringocystadenoma papilliferum of the eyelid","volume":"52","author":"Brent","year":"2017","journal-title":"Can J Ophthalmol"},{"issue":"(4)","key":"2024013013503174700_i1543-2165-148-2-215-b49","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/DAD.0b013e3182a38bb9","article-title":"Syringocystadenocarcinoma papilliferum in situ: report of a case with late recurrence","volume":"36","author":"Castillo","year":"2014","journal-title":"Am J Dermatopathol"},{"issue":"(8)","key":"2024013013503174700_i1543-2165-148-2-215-b50","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/DSS.0000000000001403","article-title":"Syringocystadenoma papilliferum in coexistence with verrucous carcinoma on the face","volume":"44","author":"Park","year":"2018","journal-title":"Dermatol Surg"},{"issue":"(4)","key":"2024013013503174700_i1543-2165-148-2-215-b51","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ad.2017.03.021","article-title":"Syringocystadenocarcinoma papilliferum: case report and review of the literature","volume":"109","author":"Agullo Perez","year":"2018","journal-title":"Actas Dermosifiliogr"},{"issue":"(1)","key":"2024013013503174700_i1543-2165-148-2-215-b52","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/IOP.0b013e318216366a","article-title":"Syringocystadenocarcinoma papilliferum of the eyelid","volume":"28","author":"Hoguet","year":"2012","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"(5)","key":"2024013013503174700_i1543-2165-148-2-215-b53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2559.1996.t01-4-297345.x","article-title":"Syringocystadenocarcinoma papilliferum","volume":"28","author":"Bondi","year":"1996","journal-title":"Histopathology"},{"issue":"(2)","key":"2024013013503174700_i1543-2165-148-2-215-b54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1524-4725.2011.01872.x","article-title":"A rare tumor: syringocystadenocarcinoma papilliferum","volume":"37","author":"Aydin","year":"2011","journal-title":"Dermatol Surg"},{"key":"2024013013503174700_i1543-2165-148-2-215-b55","doi-asserted-by":"crossref","first-page":"453874","DOI":"10.1155\/2014\/453874","article-title":"A new case of syringocystadenocarcinoma papilliferum: a rare pathology for a wide-ranging comprehension","volume":"2014","author":"Paradiso","year":"2014","journal-title":"Case Rep Med"},{"issue":"(5)","key":"2024013013503174700_i1543-2165-148-2-215-b56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/ijd.12438","article-title":"Long-standing exophytic mass in the right infratemporal region: syringocystadenocarcinoma papilliferum","volume":"53","author":"Mohanty","year":"2014","journal-title":"Int J Dermatol"},{"issue":"(12)","key":"2024013013503174700_i1543-2165-148-2-215-b57","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/DAD.0000000000000046","article-title":"Syringocystadenocarcinoma papilliferum with intraepidermal pagetoid spread on an unusual location","volume":"36","author":"Shan","year":"2014","journal-title":"Am J Dermatopathol"},{"issue":"(3)","key":"2024013013503174700_i1543-2165-148-2-215-b58","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.4081\/cp.2012.e71","article-title":"Carcino-sarcoma in a case of syringocystadenoma papilliferum: a rare entity","volume":"2","author":"Bakhshi","year":"2012","journal-title":"Clin Pract"},{"key":"2024013013503174700_i1543-2165-148-2-215-b59","doi-asserted-by":"crossref","first-page":"bcr0520114254","DOI":"10.1136\/bcr.05.2011.4254","article-title":"Syringocystadenocarcinoma papilliferum at unusual site: inherent lesional histologic polymorphism is the pathognomon","volume":"2011","author":"Abrari","year":"2011","journal-title":"BMJ Case Rep"},{"issue":"(2)","key":"2024013013503174700_i1543-2165-148-2-215-b60","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0463.2008.00027.x","article-title":"Syringocystadenocarcinoma papilliferum in situ originating from the perianal skin","volume":"117","author":"Langner","year":"2009","journal-title":"APMIS"},{"issue":"(4)","key":"2024013013503174700_i1543-2165-148-2-215-b61","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3346\/jkms.2007.22.4.762","article-title":"Syringocystadenocarcinoma papilliferum: a case report","volume":"22","author":"Park","year":"2007","journal-title":"J Korean Med Sci"},{"issue":"(7)","key":"2024013013503174700_i1543-2165-148-2-215-b62","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2559.2006.02421.x","article-title":"Syringocystadenocarcinoma papilliferum in situ with pagetoid spread: a case report","volume":"48","author":"Woestenborghs","year":"2006","journal-title":"Histopathology"},{"issue":"(3)","key":"2024013013503174700_i1543-2165-148-2-215-b63","first-page":"468","article-title":"Syringocystadenocarcinoma papilliferum: successfully treated with Mohs micrographic surgery","volume":"30","author":"Chi","year":"2004","journal-title":"Dermatol Surg"},{"issue":"(2)","key":"2024013013503174700_i1543-2165-148-2-215-b64","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1346-8138.2003.tb00363.x","article-title":"A case of syringocystadenocarcinoma papilliferum in situ occurring partially in syringocystadenoma papilliferum","volume":"30","author":"Arai","year":"2003","journal-title":"J Dermatol"},{"issue":"(1)","key":"2024013013503174700_i1543-2165-148-2-215-b65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0560.1985.tb00422.x","article-title":"Syringadenocarcinoma papilliferum","volume":"12","author":"Numata","year":"1985","journal-title":"J Cutan Pathol"},{"issue":"(4)","key":"2024013013503174700_i1543-2165-148-2-215-b66","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/DAD.0b013e3181b96c0c","article-title":"Morphologic diversity of syringocystadenocarcinoma papilliferum based on a clinicopathologic study of 6 cases and review of the literature","volume":"32","author":"Kazakov","year":"2010","journal-title":"Am J Dermatopathol"},{"issue":"(3)","key":"2024013013503174700_i1543-2165-148-2-215-b67","first-page":"405","article-title":"Syringocystadenocarcinoma papilliferum in situ of the penis","volume":"22","author":"Plant","year":"2012","journal-title":"Eur J Dermatol"},{"issue":"(11)","key":"2024013013503174700_i1543-2165-148-2-215-b68","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/cup.13534","article-title":"Syringocystadenocarcinoma papilliferum associated with atypical stroma: a hitherto undocumented variant of sarcomatoid carcinoma","volume":"46","author":"Alegria-Landa","year":"2019","journal-title":"J Cutan Pathol"},{"key":"2024013013503174700_i1543-2165-148-2-215-b69","doi-asserted-by":"crossref","first-page":"2515841419844087","DOI":"10.1177\/2515841419844087","article-title":"Syringocystadenocarcinoma papilliferum with orbital invasion: a case report with literature review","volume":"11","author":"Pagano Boza","year":"2019","journal-title":"Ther Adv Ophthalmol"},{"issue":"(2)","key":"2024013013503174700_i1543-2165-148-2-215-b70","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000524821","article-title":"Rapid development of syringocystadenocarcinoma papilliferum in an immunosuppressed liver transplant recipient","volume":"14","author":"Zilberg","year":"2022","journal-title":"Case Rep Dermatol"},{"key":"2024013013503174700_i1543-2165-148-2-215-b71","doi-asserted-by":"crossref","first-page":"101934","DOI":"10.1016\/j.eucr.2021.101934","article-title":"Genital syringocystadenocarcinoma papilliferum: an unusual location and review of the literature","volume":"40","author":"Shahidi Dadras","year":"2022","journal-title":"Urol Case Rep"},{"issue":"(12)","key":"2024013013503174700_i1543-2165-148-2-215-b72","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/DAD.0000000000002049","article-title":"Nevus sebaceous of the scalp with stepwise progression into invasive syringocystadenocarcinoma papilliferum","volume":"43","author":"Kneitz","year":"2021","journal-title":"Am J Dermatopathol"},{"issue":"(11)","key":"2024013013503174700_i1543-2165-148-2-215-b73","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/cup.14080","article-title":"A rare case of syringocystadenocarcinoma papilliferum of the breast: an institutional retrospective case review and brief literature review","volume":"48","author":"McBride","year":"2021","journal-title":"J Cutan Pathol"},{"issue":"(5)","key":"2024013013503174700_i1543-2165-148-2-215-b74","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5021\/ad.2019.31.5.559","article-title":"Syringocystadenocarcinoma papilliferum: a case report and review of the literature","volume":"31","author":"Lee","year":"2019","journal-title":"Ann Dermatol"},{"issue":"(3)","key":"2024013013503174700_i1543-2165-148-2-215-b75","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/15384047.2019.1685291","article-title":"Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss","volume":"21","author":"Frisone","year":"2020","journal-title":"Cancer Biol Ther"},{"issue":"(4)","key":"2024013013503174700_i1543-2165-148-2-215-b76","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.2016-0310","article-title":"Clinical benefit in response to palbociclib treatment in refractory uterine leiomyosarcomas with a common CDKN2A alteration","volume":"22","author":"Elvin","year":"2017","journal-title":"Oncologist"},{"issue":"(4)","key":"2024013013503174700_i1543-2165-148-2-215-b77","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/cancers13040795","article-title":"Clinical candidates targeting the ATR-CHK1-WEE1 axis in cancer","volume":"13","author":"Gorecki","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"(10271)","key":"2024013013503174700_i1543-2165-148-2-215-b78","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"issue":"(36)","key":"2024013013503174700_i1543-2165-148-2-215-b79","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","article-title":"Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"(36)","key":"2024013013503174700_i1543-2165-148-2-215-b80","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months","volume":"34","author":"Leijen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"(8)","key":"2024013013503174700_i1543-2165-148-2-215-b81","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/148\/2\/215\/3322674\/i1543-2165-148-2-215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/148\/2\/215\/3322674\/i1543-2165-148-2-215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:40:04Z","timestamp":1764790804000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/148\/2\/article-p215.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":81,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4,19]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2022-0474-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,19]]}}}